Mattia Zampieri
Overview
Explore the profile of Mattia Zampieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fumagalli C, Ponti L, Smorti M, Pozza F, Argiro A, Zampieri M, et al.
Aging Clin Exp Res
. 2024 Apr;
36(1):89.
PMID: 38598143
Background: Whether, and to what extent, frailty and other geriatric domains are linked to health status in patients with transthyretin cardiac amyloidosis (ATTR-CA) is unknown. Aims: To determine the association...
12.
Ioannou A, Cappelli F, Emdin M, Nitsche C, Longhi S, Masri A, et al.
J Am Coll Cardiol
. 2024 Mar;
PMID: 38530684
Background: Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive cardiomyopathy. The clinical course varies among individuals and there are no established measures to assess disease progression. Objectives: The goal of this...
13.
Del Franco A, Palinkas E, Bellagamba C, Biagioni G, Zampieri M, Marchi A, et al.
Circ Heart Fail
. 2024 Mar;
17(3):e011188.
PMID: 38502728
No abstract available.
14.
Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, et al.
Circulation
. 2024 Feb;
149(15):1157-1168.
PMID: 38328945
Background: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and be associated with outcome....
15.
Musumeci B, Tini G, Biagini E, Merlo M, Calore C, Ammirati E, et al.
Int J Cardiol
. 2024 Jan;
400:131784.
PMID: 38242504
Background: A minority of patients with hypertrophic cardiomyopathy (HCM) presents advanced heart failure (HF) during their clinical course, in the context of left ventricular (LV) remodeling with reduced LV ejection...
16.
Zampieri M, Schoonvelde S, Vinci M, Meattini I, Visani L, Fornaro A, et al.
Mayo Clin Proc
. 2024 Jan;
99(2):218-228.
PMID: 38180395
Objective: To describe the potential clinical cardiotoxicity of oncological treatments in a cohort of consecutive patients with hypertrophic cardiomyopathy (HCM), systematically followed-up at two national referral centers for HCM. Cardiotoxicity...
17.
Sollier J, Basler M, Broz P, Dittrich P, Drescher K, Egli A, et al.
Nat Microbiol
. 2024 Jan;
9(1):1-3.
PMID: 38177300
No abstract available.
18.
Passantino S, Chiellino S, Girolami F, Zampieri M, Calabri G, Spaziani G, et al.
Diagnostics (Basel)
. 2023 Dec;
13(24).
PMID: 38132258
Background: Cardiac involvement is reported in a significant proportion of patients with classical organic acidurias (OAs), contributing to disability and premature death. Different cardiac phenotypes have been described, among which...
19.
Zampieri M, Di Filippo C, Zocchi C, Fico V, Golinelli C, Spaziani G, et al.
Diagnostics (Basel)
. 2023 Dec;
13(24).
PMID: 38132249
Restrictive cardiomyopathy (RCM) is characterized by restrictive ventricular pathophysiology determined by increased myocardial stiffness. While suspicion of RCM is initially raised by clinical evaluation and supported by electrocardiographic and echocardiographic...
20.
Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, et al.
Blood Adv
. 2023 Nov;
7(24):7433-7444.
PMID: 37934892
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, but first-line immunochemotherapy fails to produce a durable response in about one-third of the patients. Because tumor cells...